Correlation Between Oncopeptides and Kambi Group

Can any of the company-specific risk be diversified away by investing in both Oncopeptides and Kambi Group at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oncopeptides and Kambi Group into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Oncopeptides AB and Kambi Group PLC, you can compare the effects of market volatilities on Oncopeptides and Kambi Group and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oncopeptides with a short position of Kambi Group. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oncopeptides and Kambi Group.

Diversification Opportunities for Oncopeptides and Kambi Group

0.86

Correlation Coefficient

Oncopeptides  Kambi Group

Very poor diversification

The 3 months correlation between Oncopeptides and Kambi is 0.86. Overlapping area represents the amount of risk that can be diversified away by holding Oncopeptides AB and Kambi Group PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Kambi Group PLC and Oncopeptides is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oncopeptides AB are associated (or correlated) with Kambi Group. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Kambi Group PLC has no effect on the direction of Oncopeptides i.e., Oncopeptides and Kambi Group go up and down completely randomly.

Pair Corralation between Oncopeptides and Kambi Group

Assuming the 90 days trading horizon Oncopeptides AB is expected to under-perform the Kambi Group. In addition to that, Oncopeptides is 1.55 times more volatile than Kambi Group PLC. It trades about -0.08 of its total potential returns per unit of risk. Kambi Group PLC is currently generating about -0.04 per unit of volatility. If you would invest  11,300  in Kambi Group PLC on September 2, 2024 and sell it today you would lose (1,050) from holding Kambi Group PLC or give up 9.29% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Oncopeptides AB  vs.  Kambi Group PLC

Oncopeptides AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Oncopeptides AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Kambi Group PLC

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Kambi Group PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Pair Trading with Oncopeptides and Kambi Group

The main advantage of trading using opposite Oncopeptides and Kambi Group positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oncopeptides position performs unexpectedly, Kambi Group can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kambi Group will offset losses from the drop in Kambi Group's long position.

The idea behind Oncopeptides AB and Kambi Group PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.